THJ-2201

THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.

It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.

Pharmacology
THJ-2201 acts as a full agonist with a binding affinity of 1.34 nM at CB1 and 1.32 nM at CB2 cannabinoid receptors.

Side effects
THJ-2201 has been linked to at least one hospitalization and death due to its use.

Legal status
Because of the hazards associated with recreational use of this compound, it is classified as a Schedule I controlled substance in the United States.

It is also an Anlage II controlled drug in Germany.